NCT06906822 - PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions

Melanoma

Interventions

DRUG

enfortumab vedotin

Enfortumab vedotin 1.25 mg/kg be administered on Days 1,8,22 and 29 of every 6-week cycle by IV infusion given over approximately 30 minutes.

DRUG

pembrolizumab

Pembrolizumab 400 mg on day 1 of each 42-day cycle (Q6W)

Trial Locations (13)

15006

RECRUITING

Complexo Hospitalario Universitario de A Coruña, A Coruña

28034

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

30120

RECRUITING

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

39008

RECRUITING

Hospital Universitario Marqués de Valdecilla, Santander

41013

RECRUITING

Hospital Virgen del Rocío, Seville

46014

RECRUITING

Hospital General de Valencia, Valencia

50009

RECRUITING

Hospital Universitario Miguel Servet, Zaragoza

08916

RECRUITING

Institut Català D'Oncologia - Badalona, Badalona

08028

NOT_YET_RECRUITING

Hospital Universitari Dexeus, Barcelona

08035

RECRUITING

Hospital Universitario Valle de Hebrón, Barcelona

08036

RECRUITING

Hospital Clinic de Barcelona, Barcelona